ATE517617T1 - Behandlung von parkinson erkrankung mit kape - Google Patents

Behandlung von parkinson erkrankung mit kape

Info

Publication number
ATE517617T1
ATE517617T1 AT02786994T AT02786994T ATE517617T1 AT E517617 T1 ATE517617 T1 AT E517617T1 AT 02786994 T AT02786994 T AT 02786994T AT 02786994 T AT02786994 T AT 02786994T AT E517617 T1 ATE517617 T1 AT E517617T1
Authority
AT
Austria
Prior art keywords
kape
parkinson
disease
treatment
neurodegenerative
Prior art date
Application number
AT02786994T
Other languages
English (en)
Inventor
Yansheng Du
Martin Farlow
Ruyu Du
Original Assignee
Yansheng Dr Du
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yansheng Dr Du filed Critical Yansheng Dr Du
Application granted granted Critical
Publication of ATE517617T1 publication Critical patent/ATE517617T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02786994T 2001-12-10 2002-12-10 Behandlung von parkinson erkrankung mit kape ATE517617T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33921501P 2001-12-10 2001-12-10
PCT/US2002/039458 WO2003053425A1 (en) 2001-12-10 2002-12-10 Treatment of neurodegenerative and cardiovascular disorders

Publications (1)

Publication Number Publication Date
ATE517617T1 true ATE517617T1 (de) 2011-08-15

Family

ID=23328006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02786994T ATE517617T1 (de) 2001-12-10 2002-12-10 Behandlung von parkinson erkrankung mit kape

Country Status (9)

Country Link
US (2) US20030139458A1 (de)
EP (1) EP1461025B1 (de)
JP (1) JP4511183B2 (de)
CN (1) CN100358515C (de)
AT (1) ATE517617T1 (de)
AU (1) AU2002351341A1 (de)
CA (1) CA2466928A1 (de)
TW (1) TWI335220B (de)
WO (1) WO2003053425A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
ES2473581T3 (es) 2002-05-31 2014-07-07 Proteotech Inc. Compuestos, composiciones y métodos para el tratamiento de amiloidosis y sinucleinopat�as tales como la enfermedad de Alzheimer, la diabetes de tipo 2 y la enfermedad de Parkinson
US20040167217A1 (en) * 2003-02-26 2004-08-26 Giovanni Scapagnini Neuroprotective effects of polyphenolic compounds
EP1988887A2 (de) * 2006-01-13 2008-11-12 University of South Carolina Verfahren und zusammensetzung zur behandlung von morbus parkinson
CN101652345A (zh) * 2006-12-04 2010-02-17 诺沃泰尔医疗有限公司 新型蛋白激酶调节剂和其治疗应用
CA2758016A1 (en) 2008-06-05 2009-12-10 Novotyr Therapeutics Ltd. Novel modulators of protein kinase signaling
CN101941907B (zh) * 2010-05-28 2015-04-01 毛腾淑 4-叔丁基苄基-3,4-二羟基肉桂酸酯及其用途和制备方法
CN103260614B (zh) * 2010-10-18 2016-09-14 北京脉迪法莫医药科技有限公司 联合疗法
CN103384522B (zh) * 2010-11-15 2016-09-07 帕迪有限公司 咖啡酸衍生物和它们在改善神经细胞生存力中的用途
US9770454B2 (en) 2013-07-14 2017-09-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
KR20170109589A (ko) 2015-02-05 2017-09-29 티르노보 리미티드 암 치료를 위한 irs/stat3 이중 조절제 및 항암제의 조합물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2721398A1 (de) * 1976-05-19 1977-12-01 Ciba Geigy Ag Alkylphenol-stabilisatoren
US4959503A (en) * 1986-04-11 1990-09-25 Warner-Lambert Company Diarylalkanoids having activity as lipoxygenase inhibitors
JPS62294634A (ja) * 1986-04-11 1987-12-22 ワ−ナ−−ランバ−ト・コンパニ− ジアリ−ルアルカノイドおよびその製法
JPH0678286B2 (ja) * 1988-03-18 1994-10-05 三井東圧化学株式会社 ジヒドロカフェイン酸誘導体およびそれを有効成分として含有する治療剤
DE3920616A1 (de) * 1989-06-23 1991-01-03 Boehringer Mannheim Gmbh Arzneimittel, enthaltend di-tert.-butylhydroxyphenyl-derivate sowie neue derivate
DE4126662A1 (de) * 1991-08-13 1993-02-18 Boehringer Mannheim Gmbh Neue 3,5-di-tert.butyl-4-hydroxyphenyl-derivate, verfahren zu ihrer herstellung und arzneimittel
WO1997023202A1 (en) * 1995-12-22 1997-07-03 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON Subtype-selective nmda receptor ligands and the use thereof
EP0998275A4 (de) * 1996-09-05 2003-05-02 Res Dev Foundation Inhibition des nuklearen transkriptionsfaktors nf-kappa-b durch kaffeinsäure-phenetyl-ester, dessen derivate, capsaicin (8-methyl-n-vanillyl-6-nonenamid) und resiniferatoxin
TW466115B (en) * 1996-12-10 2001-12-01 American Home Prod Pharmaceutical composition of antioxidant from equilenin
CA2281224A1 (en) * 1997-02-15 1998-08-20 Proscript, Inc. Treatment of infarcts through inhibition of nf-kappab
GB9801398D0 (en) * 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
HUP0104841A3 (en) * 1999-09-17 2002-07-29 Daiichi Suntory Pharma Co Ltd Medicaments containing benzoquinone- or condensed pyrimidine derivatives as active ingredient for treating of myocarditis, dilated cardiomyopathy and cardiac insufficiency

Also Published As

Publication number Publication date
JP2005513100A (ja) 2005-05-12
WO2003053425A1 (en) 2003-07-03
CA2466928A1 (en) 2003-07-03
CN1589137A (zh) 2005-03-02
US20100160433A1 (en) 2010-06-24
TWI335220B (en) 2011-01-01
JP4511183B2 (ja) 2010-07-28
EP1461025A1 (de) 2004-09-29
AU2002351341A1 (en) 2003-07-09
US20030139458A1 (en) 2003-07-24
EP1461025B1 (de) 2011-07-27
EP1461025A4 (de) 2009-07-29
TW200301100A (en) 2003-07-01
US8575215B2 (en) 2013-11-05
CN100358515C (zh) 2008-01-02

Similar Documents

Publication Publication Date Title
GB0223038D0 (en) Therapeutic compounds
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE122012000001I1 (de) Humane antikorper gegen CTLA-4 und deren verwendungen.
DE69925256D1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
BR0016681B1 (pt) composição amaciante de tecidos, e, método de tratamento de tecido.
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
ATE355079T1 (de) Behandlung von prostata-krebs mit anti-erbb2 antikörpern
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
BR0114054A (pt) Método para tratar alergias usando pirazóis substituìdos
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
ATE384699T1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
ATE517617T1 (de) Behandlung von parkinson erkrankung mit kape
NL1021504A1 (nl) Waterstofbehandelingsproces.
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
WO2004033423A3 (en) Anticancer compounds
DE60130365D1 (de) Die Verwendung von Rosiglitazon zur Behandlung von psychiatrischen Erkrankungen.
HK1080408A1 (en) Use of brimonidine in the treatment of dementia a nd parkinson
WO2004026258A3 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties